[go: up one dir, main page]

TR200403328T2 - Kilo alımını tedavi ve/veya önleme metotları. - Google Patents

Kilo alımını tedavi ve/veya önleme metotları.

Info

Publication number
TR200403328T2
TR200403328T2 TR2004/03328T TR200403328T TR200403328T2 TR 200403328 T2 TR200403328 T2 TR 200403328T2 TR 2004/03328 T TR2004/03328 T TR 2004/03328T TR 200403328 T TR200403328 T TR 200403328T TR 200403328 T2 TR200403328 T2 TR 200403328T2
Authority
TR
Turkey
Prior art keywords
prevention
methods
treatment
weight gain
dehydroepiandrosterone
Prior art date
Application number
TR2004/03328T
Other languages
English (en)
Inventor
Richard Denis
Deshaies Yves
Labrie Fernand
Martel Celine
Original Assignee
Endorecherche, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorecherche, Inc. filed Critical Endorecherche, Inc.
Publication of TR200403328T2 publication Critical patent/TR200403328T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Insanlar da dahil olmak üzere hassas sicak kanli hayvanlarda asiri sismanlik, karin yagi ve ensülin direncinin tibbi tedavisi ve/veya önlenmesi için yeni metotlar selektif östrojen reseptör modülatörlerinin (SERM'ler) uygulanmasini gerektirir. Dehidroepiandrosteron, dehidroepiandrosteron sülfat, androst-5-en-3b,17b-diol ve önceki öncülerin ya da östrojenin herhangi birine in vivo olarak çevrilmis bilesiklerden olusan gruptan seçilmis bir cinsiyet steroid öncüsü ya da östrojenin bir miktari ile bir SERM'in bir kombinasyonu da ayni zamanda açiklanmaktadir.
TR2004/03328T 1999-07-06 2000-07-05 Kilo alımını tedavi ve/veya önleme metotları. TR200403328T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14240799P 1999-07-06 1999-07-06

Publications (1)

Publication Number Publication Date
TR200403328T2 true TR200403328T2 (tr) 2005-03-21

Family

ID=22499734

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2004/03328T TR200403328T2 (tr) 1999-07-06 2000-07-05 Kilo alımını tedavi ve/veya önleme metotları.
TR2005/02284T TR200502284T2 (tr) 1999-07-06 2000-07-05 Kilo alımını tedavi ve/veya önleme metotları

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2005/02284T TR200502284T2 (tr) 1999-07-06 2000-07-05 Kilo alımını tedavi ve/veya önleme metotları

Country Status (25)

Country Link
US (2) US6710059B1 (tr)
EP (1) EP1196163B1 (tr)
JP (1) JP4790178B2 (tr)
KR (1) KR101141763B1 (tr)
CN (1) CN1390126B (tr)
AR (1) AR034091A1 (tr)
AT (1) ATE447947T1 (tr)
AU (3) AU5957500A (tr)
BR (1) BR0012354A (tr)
CA (1) CA2376158C (tr)
DE (1) DE60043305D1 (tr)
DK (1) DK1196163T3 (tr)
HK (1) HK1046240B (tr)
HU (1) HU230543B1 (tr)
IL (2) IL147485A0 (tr)
MX (1) MX270786B (tr)
MY (1) MY134574A (tr)
NO (1) NO329614B1 (tr)
NZ (1) NZ516453A (tr)
PL (1) PL208972B1 (tr)
RU (3) RU2327461C2 (tr)
TR (2) TR200403328T2 (tr)
TW (1) TWI359015B (tr)
WO (1) WO2001001969A2 (tr)
ZA (1) ZA200200085B (tr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) * 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
ID27922A (id) * 1998-06-11 2001-05-03 Endorech Inc KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL
US6560217B1 (en) 1999-02-25 2003-05-06 3Com Corporation Virtual home agent service using software-replicated home agents
EP1196163B1 (en) * 1999-07-06 2009-11-11 Endorecherche Inc. Pharmaceutical compositions for the treatment of insulin resistance
WO2001026651A2 (en) * 1999-10-14 2001-04-19 Endorecherche, Inc. Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance
RU2342145C2 (ru) * 2000-01-28 2008-12-27 Андорешерш, Инк. Селективные модуляторы рецептора эстрогена в комбинации с эстрогенами
MXPA04002249A (es) 2001-09-24 2004-06-29 Bayer Pharmaceuticals Corp Preparacion y uso de derivados de 1,5,6,7,-tetrahidro-pirrolo[3,2-c]piridina para el tratamiento de la obesidad.
CA2478183C (en) 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
WO2004054573A1 (en) * 2002-12-13 2004-07-01 N.V. Nutricia Method and composition for inhibiting carbohydrate digestion
US7074779B2 (en) 2003-07-02 2006-07-11 Ortho-Mcneil Pharmaceutical, Inc. Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors
HUE025651T2 (en) * 2004-10-20 2016-04-28 Endorecherche Inc Sex Steroid precursor in combination with a selective estrogen receptor modulator to prevent and treat vaginal atrophy in postmenopausal women
US20060234993A1 (en) * 2005-04-13 2006-10-19 Eric Marchewitz Use of androstane derivatives for enhancing physical performance
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
BRPI0612586A2 (pt) * 2005-06-29 2010-11-23 Wyeth Corp formulações de estrogênios conjugados e bazedoxifeno
US20090062909A1 (en) * 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
CA2615452C (en) 2005-07-15 2015-03-31 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
WO2007127363A2 (en) 2006-04-26 2007-11-08 Micell Technologies, Inc. Coatings containing multiple drugs
WO2008042909A2 (en) 2006-10-02 2008-04-10 Micell Technologies Inc. Surgical sutures having increased strength
JP5336382B2 (ja) * 2006-10-23 2013-11-06 ミセル テクノロジーズ、インコーポレイテッド コーティングの間に基板を荷電するためのホルダー
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CA2679712C (en) 2007-01-08 2016-11-15 Micell Technologies, Inc. Stents having biodegradable layers
BRPI0810370A2 (pt) * 2007-04-17 2014-10-29 Micell Technologies Inc Stent revestido, e, método para preparar um stent
EP2170418B1 (en) * 2007-05-25 2016-03-16 Micell Technologies, Inc. Polymer films for medical device coating
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100298928A1 (en) * 2007-10-19 2010-11-25 Micell Technologies, Inc. Drug Coated Stents
CN102083397B (zh) 2008-04-17 2013-12-25 米歇尔技术公司 具有生物可吸收层的支架
CA2730995C (en) * 2008-07-17 2016-11-22 Micell Technologies, Inc. Drug delivery medical device
US8834913B2 (en) * 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
WO2010111232A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Drug delivery medical device
WO2010111196A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Peripheral stents having layers
EP2411440B1 (en) * 2009-03-23 2018-01-17 Micell Technologies, Inc. Improved biodegradable polymers
JP2012522589A (ja) * 2009-04-01 2012-09-27 ミシェル テクノロジーズ，インコーポレイテッド 被覆ステント
EP3366326A1 (en) 2009-04-17 2018-08-29 Micell Technologies, Inc. Stents having controlled elution
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
AU2014201406B2 (en) * 2009-06-16 2016-08-11 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
EP2455082A4 (en) * 2009-07-16 2012-12-19 Univ Kyushu Nat Univ Corp INSULIN-PRODUCING CELL INDUCTOR, GLUCOSE-UP AMPLIFIERS AND THERAPY AGENTS FOR DIABETES OR COMPLICATIONS IN CONNECTION WITH DIABETES
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
HUE033581T2 (hu) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
KR20160088947A (ko) 2010-06-16 2016-07-26 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
EP2593039B1 (en) 2010-07-16 2022-11-30 Micell Technologies, Inc. Drug delivery medical device
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
CA2857057A1 (en) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
SG11201402564QA (en) 2011-12-16 2014-09-26 Olema Pharmaceuticals Inc Novel benzopyran compounds, compositions and uses thereof
CA2905419C (en) 2013-03-12 2020-04-28 Micell Technologies, Inc. Bioabsorbable biomedical implants
KR102079613B1 (ko) 2013-05-15 2020-02-20 미셀 테크놀로지즈, 인코포레이티드 생흡수성 생체의학적 임플란트
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
EP3395809A4 (en) * 2015-12-22 2019-06-19 Jiangsu Hengrui Medicine Co. Ltd. BENZOPIPERIDIN DERIVATIVE, PRODUCTION METHOD AND MEDICAL USE THEREOF
US20180207177A1 (en) * 2017-01-23 2018-07-26 Government Of The United States As Represented By The Secretary Of The Air Force TREATMENT OF TRIPLE NEGATIVE BREAST CANCER UTILIZING ANDROST-5-ENE-3b,17b-DIOL (b-AED), ANDROST-5-ENE-3b,7b,17b-TRIOL (b-AET) AND ESTRADIOL (E2)
CN114315851B (zh) * 2022-01-03 2023-10-24 安徽大学绿色产业创新研究院 一种光甘草定药物中间体的合成方法
JP7440838B1 (ja) 2023-07-06 2024-02-29 株式会社インタートレードヘルスケア 卵巣機能欠落生体の内臓脂肪蓄積抑制飲食品、及び卵巣機能欠落生体の内臓脂肪蓄積抑制薬

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504119B1 (fr) * 1981-04-17 1985-09-20 Aury Jean Pierre Beton isolant ainsi que son procede de fabrication
DE3117979A1 (de) * 1981-05-07 1983-01-20 Hoechst Ag, 6000 Frankfurt Neue(delta)1-pyrrolin-thiolactimaether und verfahren zu ihrer herstellung
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5254568A (en) * 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
US6060503A (en) * 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
ZA931601B (en) * 1992-03-06 1993-10-05 Squibb & Sons Inc Microsomal triglyceride transfer protein
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW275584B (tr) * 1993-06-24 1996-05-11 Fli Lilly And Co
US5446061A (en) * 1993-11-05 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
US5527788A (en) * 1994-01-18 1996-06-18 Louisiana State Univ. Medical Center Foundation Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
ZA965346B (en) * 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
RU2098330C1 (ru) * 1996-01-05 1997-12-10 Акционерное общество открытого типа "ХИТОН" Способ подачи и аэрозольного распылиения жидкого активного продукта и устройство для его осуществления
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5843984A (en) * 1996-05-09 1998-12-01 Eli Lilly And Company Sulfated benzothiophene derivatives, methods of use and formulations containing same
AU8102398A (en) * 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
AU8433898A (en) * 1997-07-10 1999-02-08 Novo Nordisk A/S Use of 3,4-diphenylchromans for the manufacture of a pharmaceutical composition for increasing insulin sensitivity
AU757206B2 (en) * 1997-08-15 2003-02-06 Duke University A method of preventing or treating estrogen-dependent diseases and disorders
JP2003525843A (ja) * 1997-10-08 2003-09-02 ジェネシスコスメティックス ライツ アンド ライセンシズ カンパニー リミテッド 脂肪細胞を含む身体部位の引き締めおよび／または縮小
UA66861C2 (uk) 1998-05-15 2004-06-15 Уайт 2-феніл-1-[4-(2-аміноетокси)бензил]індол в комбінації з естрогенами, способи лікування та продукт для лікування
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) * 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
ID27922A (id) 1998-06-11 2001-05-03 Endorech Inc KOMPOSISI FARMASETIKAL DAN PENGGUNAAN DARI ANDROST-5-ENA-3β, 17β-DIOL
AU771352B2 (en) * 1999-06-18 2004-03-18 Stephen James Cordell Finishing tool
EP1196163B1 (en) * 1999-07-06 2009-11-11 Endorecherche Inc. Pharmaceutical compositions for the treatment of insulin resistance

Also Published As

Publication number Publication date
WO2001001969A2 (en) 2001-01-11
DK1196163T3 (da) 2010-03-29
CN1390126A (zh) 2003-01-08
TW200803838A (en) 2008-01-16
NZ516453A (en) 2004-04-30
PL352993A1 (en) 2003-09-22
RU2013148518A (ru) 2015-05-10
EP1196163A2 (en) 2002-04-17
BR0012354A (pt) 2002-04-02
EP1196163B1 (en) 2009-11-11
DE60043305D1 (de) 2009-12-24
US8609695B2 (en) 2013-12-17
MY134574A (en) 2007-12-31
ZA200200085B (en) 2003-06-25
KR20020020776A (ko) 2002-03-15
RU2008101793A (ru) 2009-07-27
IL195860A (en) 2013-06-27
HUP0202363A2 (en) 2002-10-28
AR034091A1 (es) 2004-02-04
MX270786B (es) 2009-10-08
JP2003503446A (ja) 2003-01-28
MXPA02000075A (es) 2003-05-23
PL208972B1 (pl) 2011-07-29
HK1046240A1 (en) 2003-01-03
NO20020037L (no) 2002-03-04
NO329614B1 (no) 2010-11-22
HUP0202363A3 (en) 2005-02-28
AU2009200258B2 (en) 2012-01-12
TWI359015B (en) 2012-03-01
HK1046240B (en) 2010-09-30
IL147485A0 (en) 2002-08-14
AU2005229713A1 (en) 2005-12-01
RU2636498C2 (ru) 2017-11-23
CN1390126B (zh) 2012-06-13
AU5957500A (en) 2001-01-22
KR101141763B1 (ko) 2012-05-08
AU2009200258A1 (en) 2009-02-26
CA2376158C (en) 2011-03-15
RU2327461C2 (ru) 2008-06-27
US20040034000A1 (en) 2004-02-19
US6710059B1 (en) 2004-03-23
ATE447947T1 (de) 2009-11-15
TR200502284T2 (tr) 2005-08-22
NO20020037D0 (no) 2002-01-04
RU2519642C2 (ru) 2014-06-20
JP4790178B2 (ja) 2011-10-12
HU230543B1 (hu) 2016-11-28
WO2001001969A3 (en) 2001-08-02
CA2376158A1 (en) 2001-01-11

Similar Documents

Publication Publication Date Title
TR200403328T2 (tr) Kilo alımını tedavi ve/veya önleme metotları.
Sitruk-Ware Pharmacology of different progestogens: the special case of drospirenone
Godsland Oestrogens and insulin secretion
De Boer et al. Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism
Kloosterboer et al. Effects of progestagens and Org OD14 in in vitro and in vivo tumor models
TR200103456T2 (tr) Cinsiyet steroidi öncüleri ile kombinasyon halindeki bir selektif östrojen reseptör modülatörünün tıbbi kullanımları.
Boisselle et al. New therapeutic approach to the hirsute patient
Surampudi et al. Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive
SK77995A3 (en) Pharmaceutical composition for the prophylaxy or treatment of menopause symptoms, compound converted in vivo and use thereof
Mortreux et al. Hindlimb suspension in Wistar rats: Sex-based differences in muscle response
Nestler et al. Metabolism and actions of dehydroepiandrosterone in humans
Ferreira et al. Sex hormones differentially influence voluntary running activity, food intake and body weight in aging female and male rats
Rochefort et al. Cellular and molecular mechanism of action of antiestrogens
Hutchison Hypothalamic mechanisms of sexual behavior with special reference to birds
TR200200429T2 (tr) Kilo alımını tedavi ve/veya önleme metodları.
Hammond et al. Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy
Foidart et al. Advances in hormone replacement therapy: Weight benefits of drospirenone, a 17α-spirolactone-derived progestogen
Liu et al. Androgens, obesity, and sleep-disordered breathing in men
Ohlsson et al. Sex steroids and bone health in men
Sivik et al. Progesterone and levonorgestrel regulate expression of 17βHSD-enzymes in progesterone receptor positive breast cancer cell line T47D
HUE028948T2 (en) Device for the treatment of obesity
Nelson Steroidal oestrogens added to list of known human carcinogens.
Bradlow et al. Immunological properties of dehydroepiandrosterone, its conjugates, and metabolites
Frye Estradiol tends to improve inhibitory avoidance performance in adrenalectomized male rats and reduces pyknotic cells in the dentate gyrus of adrenalectomized male and female rats
Dikkeschei et al. Delta‐5‐androstenediol and its sulphate in serum and urine of normal adults and patients with endocrine diseases